rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2014-1-1-62-68rpmj-19Research ArticleОбзорыReviewПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ МЕТФОРМИНАPLEYOTROPIC EFFECTS OF METFORMINМоргуновЛ. Ю.MorgunovL. Ju.

доктор медицинских наук, профессор кафедры терапии, клинической фармакологии и скорой медицинской помощи ГБОУ ВПО «МГМСУ имени А.И.Евдокимова»  Минздрава РФ. Адрес: 127473, Российская Федерация, Москва, ул. Делегатская, д.20, стр.1 Телефон:+7 (495) 471-10-44

Morgunov Leonid Yulevich, MD, professor of therapy, clinical pharmacology and medical emergencies Moscow State University of Medicine and Dentistry named after A.I. Evdokimov 20/1, Delegatskaya, 127473, Russian Federation, Moscow Тel:+7 (495) 471-10-44,

morgunov.l.y@mail.ruГБОУ ВПО «МГМСУ имени А.И. Евдокимова» МЗ РФ (Москва, Российская Федерация) 127473, Российская Федерация, Москва, ул. Делегатская, д.20, стр.1РоссияMoscow State University of Medicine and Dentistry named after A.I. Evdokimov (Moscow, Russian Federation) 20/1, Delegatskaya, 127473, Russian Federation, MoscowRussian Federation201416012015116268Copyright © Моргунов Л.Ю., 20152015Моргунов Л.Ю.Morgunov L.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/19

Метформин, традиционно используемый для терапии сахарного диабета (СД), обладает рядом разнообразных плейотропных эффектов. Препарат, помимо сахароснижающего действия, оказывает благоприятное влияние на компоненты метаболического синдрома, оказывает благоприятное влияние на массу тела, жировую трансформацию печени, онкологические процессы, распространенность которых в популяции больных СД 2 типа увеличена.

Metformin, traditionally used for the therapy of diabetes mellitus, possesses a number of diverse pleyotropic effects. The drug, in addition to the glucose-lowering actions, has a beneficial effect on components of the metabolic syndrome, significantly reduces body weight.

сахарный диабетнеалкогольная жировая болезнь печениракожирениеdiabetes mellitusnonalcoholic fatty liver diseasecancerobesityReferencesMahmood K., Naeem M., Rahimnajjad N.A. Metformin: the hidden chronicles of a magic drug. [Journal] // Eur J Intern Med. - 2013. - Vol. 24. - pp. 20-26. - doi: 10.1016/j.ejim.2012.10.011.Mahmood K., Naeem M., Rahimnajjad N.A. Metformin: the hidden chronicles of a magic drug. [Journal] // Eur J Intern Med. - 2013. - Vol. 24. - pp. 20-26. - doi: 10.1016/j.ejim.2012.10.011.IDF Diabetes Atlas [Book]. - 2009. - 4 th Edition : p. 7.IDF Diabetes Atlas [Book]. - 2009. - 4 th Edition : p. 7.Dedov I.I., Suncov Ju.I., Kudrjakova S.V. Jekonomicheskie problemy saharnogo diabeta v Rossii [Zhurnal] // Saharnyj diabet. - 2000. - 3. - str. 56–58. (in Russian)Dedov I.I., Suncov Ju.I., Kudrjakova S.V. Jekonomicheskie problemy saharnogo diabeta v Rossii [Zhurnal] // Saharnyj diabet. - 2000. - 3. - str. 56–58. (in Russian)Dedov I.I., Shestakova M.V. Algoritmy specializirovannoj medicinskoj pomoshhi bol’nym saharnym diabetom. [Kniga]. - Moskva : [b.n.], 2013. - Izdanie shestoe, dopolnennoe.Dedov I.I., Shestakova M.V. Algoritmy specializirovannoj medicinskoj pomoshhi bol’nym saharnym diabetom. [Kniga]. - Moskva : [b.n.], 2013. - Izdanie shestoe, dopolnennoe.Mkrtumjan A.M. Profilaktika saharnogo diabeta tipa 2 [Zhurnal] // Spravochnik poliklinicheskogo vracha . - 2006. - 3. - str. 17-22.Mkrtumjan A.M. Profilaktika saharnogo diabeta tipa 2 [Zhurnal] // Spravochnik poliklinicheskogo vracha . - 2006. - 3. - str. 17-22.Scheen A.J., Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. [Journal] // Diabetes Metab. - 2013. - Vol. 39. - pp. 179-190.Scheen A.J., Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. [Journal] // Diabetes Metab. - 2013. - Vol. 39. - pp. 179-190.Scarpello J.H.B., Howlett H.C.S. Metformin therapy and clinical uses [Journal] // Diab Vasc Dis Res. - 2008. - Vol. 5. - pp. 157–167.Scarpello J.H.B., Howlett H.C.S. Metformin therapy and clinical uses [Journal] // Diab Vasc Dis Res. - 2008. - Vol. 5. - pp. 157–167.Ajjan R.A., Grant P.J. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. [Journal]. - 2006. - Vol. 3. - pp. 147-158.Ajjan R.A., Grant P.J. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. [Journal]. - 2006. - Vol. 3. - pp. 147-158.De Aquiar L.G., Bahia L.R., Villela N., et al. Metformin improves endothelial vascular reactivity in first–degree relatives of type diabetic patient with metabolic syndrome and normal glucose tolerance.[Journal] // Diabetes Care. - 2006. - 5 : Vol. 29. - pp. 1083–1089.De Aquiar L.G., Bahia L.R., Villela N., et al. Metformin improves endothelial vascular reactivity in first–degree relatives of type diabetic patient with metabolic syndrome and normal glucose tolerance.[Journal] // Diabetes Care. - 2006. - 5 : Vol. 29. - pp. 1083–1089.Viollet B., Guigas B., Garcia N. S. Cellular and molecular mechanisms of metformin: an overview. [Journal] // Clin Sci (Lond). - 2012. - Vol. 122. - pp. 253–270.Viollet B., Guigas B., Garcia N. S. Cellular and molecular mechanisms of metformin: an overview. [Journal] // Clin Sci (Lond). - 2012. - Vol. 122. - pp. 253–270.Chang S.H., Wu L.S., Chiou M.J., et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. [Journal]. - 2014. - Vol. 13. - p. 123.Chang S.H., Wu L.S., Chiou M.J., et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. [Journal]. - 2014. - Vol. 13. - p. 123.Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. [Journal] // Ann Intern Med. - 2002. - Vol. 137. - pp. 25-33.Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. [Journal] // Ann Intern Med. - 2002. - Vol. 137. - pp. 25-33.Malin S.K., Kashyap S.R. Effects of metformin on weight loss: potential mechanisms. [Journal] // Curr Opin Endocrinol Diabetes Obes. - 2014. - p. [Epub ahead of print].- doi: 10.1097/ MED.0000000000000095.Malin S.K., Kashyap S.R. Effects of metformin on weight loss: potential mechanisms. [Journal] // Curr Opin Endocrinol Diabetes Obes. - 2014. - p. [Epub ahead of print].- doi: 10.1097/ MED.0000000000000095.Barskova V.G. , Eliseev M.S. , Nasonov E.L. i dr. Ispol’zovanie Siofora ( Siofora ) u pacientov s podagroj i rezistentnost’ju k insulinu (rezul’taty pilotnogo 6-mesjachnye issledovanija). [Zhurnal] // Terapevicheskij arhiv. - 2005 g.. - 12 : T. 77. - str. 44-49.Barskova V.G. , Eliseev M.S. , Nasonov E.L. i dr. Ispol’zovanie Siofora ( Siofora ) u pacientov s podagroj i rezistentnost’ju k insulinu (rezul’taty pilotnogo 6-mesjachnye issledovanija). [Zhurnal] // Terapevicheskij arhiv. - 2005 g.. - 12 : T. 77. - str. 44-49.Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. [Journal] // World J Gastroenterol. - 2014. - Vol. 20. - pp. 8351-8363.Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. [Journal] // World J Gastroenterol. - 2014. - Vol. 20. - pp. 8351-8363.Rouabhia S., Milic N., Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. [Journal] // Expert Rev Gastroenterol Hepatol. - 2014. - Vol. 8. - pp. 343-9. - doi: 10.1586/17474124.2014.894880.Rouabhia S., Milic N., Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. [Journal] // Expert Rev Gastroenterol Hepatol. - 2014. - Vol. 8. - pp. 343-9. - doi: 10.1586/17474124.2014.894880.Razavizade M., Jamali R., Arj A., et al. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. [Journal] // Hepat Mon. - 2013. - Vol. 13. - e9270. - doi: 10.5812/hepatmon.9270.Razavizade M., Jamali R., Arj A., et al. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. [Journal] // Hepat Mon. - 2013. - Vol. 13. - e9270. - doi: 10.5812/hepatmon.9270.Garinis G.A., Fruci B., Mazza A., et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. [Journal] // Int J Obes (Lond). - 2010. - Vol. 34. - pp. 1255- 64. - doi: 10.1038/ijo.2010.40.Garinis G.A., Fruci B., Mazza A., et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. [Journal] // Int J Obes (Lond). - 2010. - Vol. 34. - pp. 1255- 64. - doi: 10.1038/ijo.2010.40.Sivalingam V.N., Myers J., Nicholas S. et al. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. [Journal] // Hum Reprod Update. - 2014. - Vol. 20. - pp. 853-868. - doi: 10.1093/humupd/dmu037.Sivalingam V.N., Myers J., Nicholas S. et al. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. [Journal] // Hum Reprod Update. - 2014. - Vol. 20. - pp. 853-868. - doi: 10.1093/humupd/dmu037.Hajjar J., Habra M.A., Naing A. Metformin: an old drug with new potential. [Journal] // Expert Opin Investig Drugs. - 2013. - Vol. 22. - pp. 1511-7. - doi: 10.1517/13543784.2013.833604.Hajjar J., Habra M.A., Naing A. Metformin: an old drug with new potential. [Journal] // Expert Opin Investig Drugs. - 2013. - Vol. 22. - pp. 1511-7. - doi: 10.1517/13543784.2013.833604.Walker E.J., Ko A.H., Holly E.A., Bracci P.M. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. [Journal] // Int J Cancer. - 2014. - doi: 10.1002/ijc.29120.Walker E.J., Ko A.H., Holly E.A., Bracci P.M. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. [Journal] // Int J Cancer. - 2014. - doi: 10.1002/ijc.29120.Kim T.H., Suh D.H., Kim M.K., Song Y.S. Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer. [Journal] // Biomed Res Int. - 2014. - Vol. 2014. - p. 132702.Kim T.H., Suh D.H., Kim M.K., Song Y.S. Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer. [Journal] // Biomed Res Int. - 2014. - Vol. 2014. - p. 132702.Xu H., Aldrich M.C., Chen Q., et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. [Journal] // J Am Med Inform Assoc. - 2014. - pii: amiajnl-2014-002649. doi: 10.1136/amiajnl-2014-002649.Xu H., Aldrich M.C., Chen Q., et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. [Journal] // J Am Med Inform Assoc. - 2014. - pii: amiajnl-2014-002649. doi: 10.1136/amiajnl-2014-002649.Becker C., Jick S.S., Meier C.R., Bodmer M. Metformin and the risk of head and neck cancer: a case-control analysis. [Journal] //Diabetes Obes Metab. - Jul 7, 2014. - doi: 10.1111/dom.12351.Becker C., Jick S.S., Meier C.R., Bodmer M. Metformin and the risk of head and neck cancer: a case-control analysis. [Journal] //Diabetes Obes Metab. - Jul 7, 2014. - doi: 10.1111/dom.12351.Lega I.C., Shah P.S., Margel D., et al. The effect of metformin on mortality following cancer among patients with diabetes. [Journal] // Cancer Epidemiol Biomarkers Prev. - 2014. - Vol. 23. - doi: 10.1158/1055-9965.EPI-14-0327.Lega I.C., Shah P.S., Margel D., et al. The effect of metformin on mortality following cancer among patients with diabetes. [Journal] // Cancer Epidemiol Biomarkers Prev. - 2014. - Vol. 23. - doi: 10.1158/1055-9965.EPI-14-0327.Lu W.R., Defilippi J., Braun A. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. [Journal] // Ann Pharmacother. - 2013. - Vol. 47. - doi: 10.1177/1060028013505428.Lu W.R., Defilippi J., Braun A. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. [Journal] // Ann Pharmacother. - 2013. - Vol. 47. - doi: 10.1177/1060028013505428.

The authors declare that there are no conflicts of interest present.